|Articles|August 1, 2002

August 2002
Volume 8
Issue 8

The Comparative Clinical and Economic Benefits of Drugs Should be Established and Discussed as Part of any Formulary Decision Process

Author(s)Mary S. Richardson, PharmD, Brian W. Bowers, PharmD, Jonathan L. Petrie, MD. Author Reply by Lisa K. Mannix, MD

Articles in this issue

over 23 years ago

Article

A New Era of Leadership

over 23 years ago

Article

The Potential of Pill Splitting to Achieve Cost Savings

over 23 years ago

Article

Rational Use of Antibiotics to Treat Respiratory Tract Infections

over 23 years ago

Article

Reducing Cesarean Delivery Rates in Managed Care Organizations

over 23 years ago

Article

Recombinant Human Erythropoietin Usage in a Large Academic Medical Center

over 23 years ago

Article

Coronary Artery Bypass Grafting in Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

The Comparative Clinical and Economic Benefits of Drugs Should be Established and Discussed as Part of any Formulary Decision Process

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care

Semaglutide Shows Promise for Steatohepatitis Resolution in MASH

Advancing Biomarker Testing Across GU, Lung, and Myeloma Care

Smart Speaker Improves Mental Health, A1C in Older Adults With Diabetes

Federal Prevention Solutions to Homelessness Improved Health Outcomes in VA Patients